Biological treatment strategies
Evening conference
unreveiled person
25-05-07,
18:25 CET,
14 min
Description
Interventions
Drugs, Monoclonal antibodies and antibody drug conjugates (L01F), Antineoplastic and immunomodulating agents (L), Antineoplastic agents (L01), Daratumumab (L01FC01), CD38 (Clusters of Differentiation 38) inhibitors (L01FC)
Research projects
2
Research areas
3
Research types
1
Research projects
Treatment with daratumumab injections in moderate to severe ME/CFS
Project status:
Completed
Country:
Norway
Principal investigator:
Øystein Fluge, Olav Mella
Organisations:
Haukeland University Hospital
Research period:
2022-04
to not available
to not available
Research types:
Clinical research
Research areas:
Immune system dysfunction
Plasma cell targeting using the anti-CD38 antibody daratumumab in patients with ME/CFS – a randomized, placebo-controlled and double-blind phase II study
Project status:
Ongoing
Country:
Norway
Principal investigator:
Øystein Fluge
Organisations:
Haukeland University Hospital
Research period:
2025-06
to 2026-12
to 2026-12
Research types:
Clinical research
Research areas:
Immune system dysfunction
Contact
ME/CFS Research Foundation
Ballindamm 27, 20095 Hamburg, Germany
Copyright © 2022 ME/CFS Research Foundation
Imprint -
Data privacy statement